OncoMatch/Clinical Trials/NCT07851493
Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)
Official title: Exercise Phenotyping Prior to Chemotherapy Initiation in Patients With Newly Diagnosed Multiple Myeloma Without Resting Echocardiographic Signs of Cardiac Involvement
Is NCT07851493 recruiting? Yes, currently enrolling (Oct 2026).
MM-Exercise is a prospective, single-centre, observational pilot study of patients with newly diagnosed multiple myeloma who have not yet started chemotherapy and whose resting echocardiogram is unremarkable or only mildly abnormal (preserved left ventricular ejection fraction \[LVEF\] ≥50%, at most grade I diastolic dysfunction). The study tests whether a relevant proportion of these patients already exhibit a central (cardiac) limitation of exercise capacity - defined as a cardiac output to oxygen uptake slope (CO/VO2 slope) below 5 - despite the absence of overt cardiac disease on resting assessment, and whether this exercise-derived marker correlates with subclinical myocardial tissue abnormalities on cardiac magnetic resonance imaging (CMR) and with heart-failure hospitalisation and mortality over 12 months. Eighty patients referred in comparable numbers from the haemato-oncology departments will undergo a single comprehensive baseline assessment (medical and sports history, cardiac biomarkers, resting echocardiography, 6-minute walk distance, combined cardiopulmonary exercise testing with stress echocardiography \[CPETecho\], and CMR with T1-/T2-mapping and late gadolinium enhancement) prior to chemotherapy initiation, followed by in-person clinical follow-up visits 3 and 12 months after each patient's own baseline visit.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Demographics
Prior therapy
Lab requirements
Blood counts
haemoglobin ≥8 g/dL at baseline
Kidney function
Estimated glomerular filtration rate ≥30 mL/min/1.73m², no contraindication to gadolinium-based contrast agents
Cardiac function
Resting echocardiogram with preserved left ventricular ejection fraction (≥50%) and at most mild (grade I) diastolic dysfunction with no echocardiographic signs of clinically manifest cardiac involvement; no NYHA Class IV heart failure or recent decompensated heart failure requiring inpatient recompensation; no suspected new or progressive coronary artery disease
Resting echocardiogram with preserved left ventricular ejection fraction (≥50%) and at most mild (grade I) diastolic dysfunction with no echocardiographic signs of clinically manifest cardiac involvement; New York Heart Failure Association Class IV heart failure, or recent decompensated heart failure requiring inpatient recompensation [excluded]; Suspected new or progressive coronary artery disease [excluded]; Estimated glomerular filtration rate <30 mL/min/1.73m², or contraindication to gadolinium-based contrast agents [excluded]; Severe anaemia, defined as haemoglobin <8 g/dL at baseline [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07851493 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages